PMV PHARMACEUTICALS INC's ticker is PMVP and the CUSIP is 69353Y103. A total of 106 filers reported holding PMV PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.78 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,959,041 | +6.3% | 807,563 | +8.3% | 0.00% | 0.0% |
| Q2 2023 | $4,665,790 | +46.8% | 745,334 | +11.9% | 0.00% | – |
| Q1 2023 | $3,177,349 | +56076.6% | 666,111 | +2.5% | 0.00% | -100.0% |
| Q4 2022 | $5,656 | -99.9% | 650,175 | +0.8% | 0.00% | 0.0% |
| Q3 2022 | $7,677,000 | -4.7% | 645,141 | +14.1% | 0.00% | 0.0% |
| Q2 2022 | $8,058,000 | -14.5% | 565,533 | +25.0% | 0.00% | 0.0% |
| Q1 2022 | $9,421,000 | -11.0% | 452,503 | -1.3% | 0.00% | 0.0% |
| Q4 2021 | $10,587,000 | -18.0% | 458,328 | +5.7% | 0.00% | -50.0% |
| Q3 2021 | $12,917,000 | +8.6% | 433,473 | +24.5% | 0.00% | 0.0% |
| Q2 2021 | $11,893,000 | +47.0% | 348,181 | +41.5% | 0.00% | +100.0% |
| Q1 2021 | $8,093,000 | -46.5% | 246,086 | +0.1% | 0.00% | -66.7% |
| Q4 2020 | $15,121,000 | +1191.3% | 245,844 | +645.0% | 0.00% | – |
| Q3 2020 | $1,171,000 | – | 33,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Euclidean Capital LLC | 4,179,416 | $257,076,000 | 54.42% |
| INTERWEST VENTURE MANAGEMENT CO | 6,469,911 | $397,964,000 | 49.71% |
| Octagon Capital Advisors LP | 250,000 | $15,378,000 | 5.33% |
| Boxer Capital, LLC | 2,268,236 | $139,519,000 | 4.48% |
| COMMODORE CAPITAL LP | 125,000 | $7,689,000 | 4.18% |
| Orbimed Advisors | 7,330,423 | $450,894,000 | 3.95% |
| Asymmetry Capital Management, L.P. | 96,595 | $5,942,000 | 2.71% |
| Avoro Capital Advisors LLC | 2,350,267 | $130,536,000 | 2.25% |
| RA Capital Management | 1,710,265 | $105,198,000 | 1.47% |
| HighVista Strategies LLC | 22,654 | $1,393,000 | 0.89% |